Compare · ABT vs HYFT
ABT vs HYFT
Side-by-side comparison of Abbott Laboratories (ABT) and MindWalk Holdings Corp. (HYFT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and HYFT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $175.37B, about 2571.4x HYFT ($68.2M).
- Over the past year, ABT is down 19.1% and HYFT is down 16.6% - HYFT leads by 2.5 points.
- ABT has been more active in the news (10 items in the past 4 weeks vs 7 for HYFT).
- ABT has more recent analyst coverage (25 ratings vs 0 for HYFT).
- Company
- Abbott Laboratories
- MindWalk Holdings Corp.
- Price
- $100.68+1.91%
- $1.46+3.55%
- Market cap
- $175.37B
- $68.2M
- 1M return
- +11.09%
- -1.02%
- 1Y return
- -19.08%
- -16.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 10
- 7
- Recent ratings
- 25
- 0
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Roman Michael F
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- EXECUTIVE VICE PRESIDENT Morrone Louis H. covered exercise/tax liability with 269 units of Common shares without par value, decreasing direct ownership by 0.35% to 76,574 units (SEC Form 4)
- Robert W. Baird initiated coverage on Abbott Labs with a new price target
- EVP, GC AND SECRETARY Cushman Elizabeth C. covered exercise/tax liability with 560 units of Common shares without par value, decreasing direct ownership by 1% to 38,013 units (SEC Form 4)
Latest HYFT
- As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22
- SEC Form F-3 filed by MindWalk Holdings Corp.
- SEC Form 6-K filed by MindWalk Holdings Corp.
- MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2026 on July 22, 2026
- SEC Form 6-K filed by MindWalk Holdings Corp.
- MindWalk Holdings Corp. (NASDAQ: HYFT) Added to the Russell 3000E Index, Expanding Institutional Investment Opportunity
- SEC Form 6-K filed by MindWalk Holdings Corp.
- The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It
- SEC Form 6-K filed by MindWalk Holdings Corp.
- MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery